跳至主要内容
临床试验/NCT03291652
NCT03291652招募中不适用

Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential

Chinese University of Hong Kong1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2010年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
140
试验地点
1
主要终点
The plaque morphology of high-risk IAD may be distinct from the silent ones.

研究概览

简要总结

The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).

详细描述

Potential candidates will undergo a cranial MRI and MR angiography. Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery will proceed to a 30-minute TCD monitoring for MES an angiograms will be analyzed by investigators blind to subjects' clinical information. All recruited patients will receive standard medical therapy throughout the investigation period.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
30 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria for the Symptomatic Group:
  • Patient is 30 to 85 years of age, inclusive.
  • Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD.
  • Patient who has no contra-indication for the proposed imaging tests.
  • Patient understands the purpose and requirements of the study, and has provided an informed consent.
  • Inclusion Criteria for the Asymptomatic Group:
  • Patient is 30 to 85 years of age, inclusive.
  • Patient who has a high-grade (>60%) intracranial stenosis (signal void in MR angiography) but without infarct in the corresponding vascular territory in DWI or T2-weighted sequence.
  • Patient has no MES detected on TCD examination.
  • Patient who has no contra-indication for the proposed imaging tests.
  • Patient understands the purpose and requirements of the study, and has provided an informed consent.

排除标准

  • Subject who meets one or more of the following criteria cannot be recruited in the study:
  • Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc.
  • A tandem stenosis >50% at proximal internal carotid artery.
  • Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets <100 x 109/L), coagulopathy (INR >1.5).
  • A medical condition that would not allow the patient to adhere to the protocol or complete the study.

研究组 & 干预措施

Symptomatic stroke patient

DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.

2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.

Diagnosis procedure: DSA/3DRA

干预措施: DSA/3DRA (Diagnostic Test)

Asymptomatic stroke patient

DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.

2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.

Diagnosis procedure: DSA/3DRA

干预措施: DSA/3DRA (Diagnostic Test)

结局指标

主要结局

The plaque morphology of high-risk IAD may be distinct from the silent ones.

时间窗: Dec, 2020

The morphological attributes (surface outline, angulations and plaque volume) and collateral grading will be compared between symptomatic and asymptomatic group.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Leung Wai Hong Thomas

Professor

Chinese University of Hong Kong

研究点 (1)

Loading locations...

相似试验